NCCN and BCBS TEC conclude that tumor testing for KRAS mutation offers clinical utility, and testing is available outside of research settings in clinical practice.  However, we did not identify studies reporting physician and patient acceptance or population-based health outcomes data from use in clinical practice. The gene discussed is KRAS; the disease is neoplasm.